

SUBJECT INDEX

- accelerated life testing 4, 111
activation rate 4, 154–155
Akaike Information Criterion (AIC) 4,
9–10, 12, 18–20, 25, 29–30, 35–36, 43,
48, 55, 60, 62, 75–76, 174–175, 200
aleatoric uncertainty 181
allometric scaling 75, 224
- Bayes Information Criterion (BIC) 5,
169–170, 172, 174–178, 188, 195,
218–219
Bayesian Model Averaging (BMA) 4–5,
7, 148–149, 166–169, 173, 175–178,
180–182, 184, 186, 194–196, 219–221,
223
Benchmark Dose (BMD) 4, 6–8, 10–12,
20–24, 26, 31–35, 41, 43–44, 52, 55–57,
60–62, 64, 70–71, 74–79, 86, 105,
115–117, 119–120, 124–125, 128–129,
133, 135, 138, 141, 145, 148, 160–163,
166–168, 170–172, 177, 187–189,
194–195, 199–203, 217–222, 224
Benchmark Dose Lower Bound
(BMDL) 10–12, 20–24, 26, 31–32,
34–41, 43–44, 61, 67, 69–70, 148–149,
160–163, 167–168, 171–172, 177,
187–188, 195–196, 200, 202–203,
217, 221, 224
benchmark dose software 4, 8, 165, 170,
177, 194
benchmark response 10, 18, 21,
38, 148, 160–161, 167,
220
binomial uncertainty 18, 54, 56, 75, 78,
116, 118–119, 121–123, 135, 137–138,
207, 210
bootstrap 4–5, 17–22, 25–29, 31–33,
42, 44, 46, 167, 171–172, 181, 187,
194, 220
cytotoxicity 88–89
dirichlet process prior 5, 147
Effective Dose (ED) 20–22, 26,
31–32
Effective Dose Lower bound (EDL)
20–22, 26, 31–32
epistemic uncertainty 88, 181
extra risk 10, 61, 199–203
frambozadrine 8, 12–13, 17–23,
29, 31–32, 37, 40, 43, 46, 52, 54–55,
57, 62–63, 65–67, 70, 72, 74–77,
88, 101, 120–133, 173, 188, 219,
220–222

- gamma model 47
- gibbs sampler 113, 115, 121, 136, 148
- Gibbs Variable Selection (GVS)
169–170, 174–177
- hyperkeratosis 12, 19, 62, 101–102, 120,
155, 173
- Inhalation Unit Risks (IUR) 23, 25, 27–28
- isotonic regression 4–5, 7, 51–52, 54, 75,
83–84, 87, 91–92, 100–102, 107–108,
110, 152, 218, 220
- isotonic uncertainty 74–75, 79, 116,
121–122
- Iterative Proportional Fitting (IPF) 52,
57–60
- log logistic model 8–11, 56–57, 60–61, 78
- log probit model 76, 92
- log-logistic model 56–57, 61, 78–79
- low-dose extrapolation 84, 94, 103, 108,
212, 221
- Markov Chain Monte Carlo (MCMC)
113, 160–161, 169, 171, 176, 178, 181,
195–198, 200, 220
- Michaelis-Menten 154, 156–157
- model uncertainty 26, 51, 83–84, 94, 166,
174, 181, 189–191, 193, 195, 219
- monotonicity 36, 48–49, 52, 82–85, 87,
92–93, 102, 107–108, 110, 121–122,
124–125, 129, 133, 135, 137–138,
144–146, 178, 222
- multistage model 20–27, 29, 31–33, 35,
46, 62, 76, 92, 156, 198, 200, 204, 220
- nectorine 8, 12–13, 17, 23, 25–28, 31,
33–35, 52, 57, 69–70, 74, 76, 78, 88–89,
129, 132–135, 198, 200–203, 220, 222
- non-parametric bayes 111, 150, 152, 218,
220
- non-parametric bayesian 112, 115–116,
122–135, 137, 139–145, 147, 152
- observational uncertainty 52, 54, 57–58,
61, 65, 71, 75, 87, 91, 93–94, 96, 100,
102, 105, 107–110, 116, 145, 218, 221,
223
- olfactory epithelial neuroblastoma 12,
23, 25–28, 69, 129, 133–134
- parameter uncertainty 95, 189, 218–219
- persimionate 13, 17, 29–32, 35, 41, 43, 45,
52, 70, 72–75, 79, 80, 88, 135–145,
219–220, 222
- pharmacodynamics 89
- pharmacokinetics 89, 184, 192
- Point Of Departure (POD) 6, 20
- Pooling Adjacent Violators (PAV)
54–55, 102, 116, 129, 146, 151
- potency curve 115, 117, 120, 129, 135,
147–148, 160–163, 218, 220
- probabilistic inversion 51–52, 57, 60,
75–76, 78, 83, 85, 87, 91, 93, 96–97,
102, 107–108, 218, 220
- probit model 76, 92, 171
- profile likelihood 18, 42, 94, 202
- Reference Dose (RfD) 20
- Resources for the Future 1, 45, 51, 107,
109, 147, 165
- respiratory epithelial adenoma 12–13,
23, 25–28, 33–35, 69, 129, 133–134, 200
- reverse jump MCMC 178, 181
- Safe Drinking Water Act 2
- S-PLUS 17
- U.S. EPA Office of Research and
Development (ORD) 1, 4, 17, 34
- U.S. EPA National Center of
Environmental Assessment (NCEA)
1, 6–7, 150
- Weibull model 12, 20–27, 29, 31–33,
35–36, 170, 177, 222
- WinBUGS 175, 200–203